Akums Drugs & Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,342 Cr +31.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AD

Akums Drugs & Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,158Cr
+9.7% YoY
−0.2% QoQ
Net profit
₹81Cr
−46% YoY
+19.1% QoQ
Margin
13%
+4 pp YoY
0 pp QoQ
Price₹750
Market cap₹11.4K Cr
P/E37.5

The short version

CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).

From Akums Drugs & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue.
  • Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up.
  • Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth.
  • Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a few quarters.
  • Oral solid facility expansion underway to support volume growth.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
  • Ongoing expansion of the oral solid facility to support over 20% volume growth.
  • Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway.
  • Focus is on utilizing existing advanced injectable and hormone facilities.
  • Evaluating inorganic opportunities in branded portfolios, though current market valuations are high.
  • SAP S/4HANA digital transformation and Darwinbox HR implementation underway for operational efficiency.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years.
  • For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores).
  • The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28.
  • The Zambia contract will contribute approximately $25 million annually in FY27 and FY28.
  • These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results — key figures

Akums Drugs & Pharmaceuticals Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,1581,056+9.7%1,160-0.2%
Operating profit (EBITDA)15294+61.7%147+3.4%
Operating margin13%9%+4 pp13%0 pp
Profit before tax12175+61.3%100+21%
Net profit (PAT)81150-46%68+19.1%
EPS (₹)5.389.38-42.6%4.21+27.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results?

CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?

Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.